Articles Archive:

Bookcase - Oncology under the microscope


This latest edition of Cancer: Principles and Practice of Oncology is a one-stop shop for everything you ever wanted to know about oncology.

Impact Factor - Relapsed Hodgkin's lymphoma: new twist to the standard regimen

Results of a multicentre study show that a sequential high-dose chemotherapy variant of the standard treatment is safe and effective in relapsed Hodgkin's patients.

Impact Factor - Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?

A study using hepatic arterial infusion to deliver treatment to colorectal cancer patients with liver metastases is unlikely to lead to wholesale changes in clinical practice, but may spur new studies into the role of local delivery of triple combination chemotherapy in these patients.

Newsround - N E W S R O U N D

Selected press reports compiled by the ESO Cancer Media Centre

Impact Factor - Are metastatic testicular tumours curable with high-dose chemotherapy and stem-cell rescue?

A retrospective study has shown that haematopoietic stem cell rescue in tandem with high-dose chemotherapy should be considered a major treatment option in patients with testicular cancer following first-salvage chemotherapy and/or in cisplatin-refractory disease.

Impact Factor - Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer

Postoperative radiotherapy with or without chemotherapy remains part of the standard treatment regimen to improve locoregional control for patients with head and neck cancer who have adverse pathologic factors after surgery. Whether an overall survival benefit can be expected remains unclear.

e-Grand Round - Decision making for systemic treatment of non-small-cell lung cancer


Non-small-cell lung cancers (NSCLC) covers a heterogeneous group of diseases, accounting for around 80% of all lung cancers, which were previously lumped together because there was no apparent reason to use different therapeutic approaches for the various histologies. This has now changed, and choosing the best treatment option for NSCLC patients is increasingly complex.

Focus - Chemobrain: delving into possible mechanisms


‘Chemobrain' is an informal term coined by patients who are – or were – on chemotherapy, to express the feeling of being not quite switched on or able to think clearly and focus on the tasks in hand. Recent studies have begun to identify the mechanisms by which it works, who is most at risk and how to alleviate its effects.

Impact Factor - Bortezomib in newly diagnosed multiple myeloma

Preclinical studies have shown that, in addition to showing anti-multiple-myeloma activity as single agents, new agents such as bortezomib also enhance the efficacy of chemotherapy and steroids. A randomised trial has now established that bortezomib prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.

Newsround - Newsround

Selected reports edited by Janet Fricker

Masterpiece - Vested interests are undermining our efforts to beat cancer - The worries of a battle-hardened German oncologist


Cancer treatment is at a critical juncture, says Dieter K Hossfeld, veteran campaigner for the recognition of medical oncology in Germany. Future progress, he believes, depends on reasserting the interests of society at large over those of the pharmaceutical industry, the medical establishment and even individual patients.

Best Cancer Reporter Award - The ‘no miracle cure' story


The story of step-by-step progress, with occasional leaps forward and frequent setbacks, is not one the media enjoys telling. But it does need to be told if patients and society are to learn to live with cancer as a chronic disease. Linda Geddes received a Best Cancer Reporter Award for her article Living with the Enemy, which made an easy read of a complex story, and is reprinted below. Linda

Newsround - Newsround

Selected reports edited by Janet Fricker

e-Grand Round - Neurological side-effects caused by recently approved chemotherapy drugs


How can you get the greatest efficacy from neurotoxic drugs without putting patients at risk of acute or chronic damage to their nervous system?

e-Grand Round - Optimising dose-dense regimens for early breast cancer


Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added.

Impact Factor - Aprepitant and control of emesis induced by five-day chemotherapy

Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving five-day cisplatin-containing chemotherapy, a new trial shows. Some needs in antiemetic therapy remain unmet, including control of emesis with multiple-day chemotherapy and control of nausea.

Newsround - Newsround

Selected reports edited by Janet Fricker

Cover Story - Marcel Verheij: Revolutionising radiotherapy


Could intelligent combinations of drugs and radiation take precision radiotherapy to new levels? Marcel Verheij believes so, but may struggle to prove it without a fairer share of funding

Cover Story - Frederic Amant: building the evidence base for saving mother and child


Understanding the impact of treating the mother on the long-term health of her unborn child has long been held back by logistical and ethical obstacles to researching this rare patient population. Frédéric Amant took up the challenge.

e-Grand Round - Recognising and reducing the risk of chemotherapy extravasation

When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future treatment cycles, and undermine their trust in their medical team. Knowing how to assess and reduce the risks, and what to do when things go wrong, is essential.